List view / Grid view
8 September 2015 | By Victoria White
The trial will measure immune responses following administration of Pennvax-GP in four groups of healthy subjects receiving the vaccine with and without an immune activator (IL-12)...
22 July 2015 | By Victoria White
Detailed 48-week data from a Phase 3 study evaluating E/C/F/TAF regimen in patients with HIV-1 was presented at the 8th IAS Conference...
22 July 2015 | By Victoria White
Bristol-Myers Squibb has announced additional Phase IIa data for BMS-955176, a novel investigational agent designed to prevent the maturation of HIV-1...
21 July 2015 | By Victoria White
The FDA has granted Breakthrough Therapy Designation to BMS-663068 for the treatment of HIV-1 infection in heavily treatment-experienced adult patients...
16 July 2015 | By Victoria White
The EC has approved Evotaz tablets in combination with other antiretroviral agents for the treatment of HIV-1 infected adults...
3 July 2015 | By Victoria White
ViiV Healthcare and Desano Pharmaceuticals have announced a strategic manufacturing agreement to enable production of dolutegravir in China...
2 July 2015 | By Victoria White
Gilead Sciences has submitted a NDA to the FDA for an investigational, once-daily single tablet regimen for the treatment of HIV-1 infection...
1 July 2015 | By Victoria White
Cuba has become the first country in the world to receive validation from WHO that it has eliminated mother-to-child transmission of HIV and syphilis...
23 June 2015 | By Victoria White
Latest figures published by Public Health England (PHE) show there were 439,243 sexually transmitted infections (STIs) reported in England in 2014...
18 June 2015 | By Victoria White
Roche has been selected to provide HIV-1 viral load and early infant diagnostic technologies for the Global Fund...
29 May 2015 | By Victoria White
Gilead’s MAA for a fixed-dose combination of emtricitabine and tenofovir alafenamide (F/TAF) has been fully validated and is now under evaluation by the EMA..
28 May 2015 | By Victoria White
A trial has found that HIV-infected individuals have a lower risk of developing AIDS or other serious illnesses if given antiretroviral drugs sooner...
13 April 2015 | By Victoria White
ABIVAX, a biotechnology company developing first-in-class anti-viral drugs and vaccines, has announced publication of the mechanism of action of ABX464...
8 April 2015 | By Victoria White
Gilead has submitted a NDA to the FDA for an investigational fixed-dose combination of F/TAF for the treatment of HIV-1 infection...
24 March 2015 | By Victoria White
Janssen Health Policy Centre (Janssen Pharmaceutica NV) today unveiled the EU Disease Lens: a digital dashboard that brings insight into 15 major diseases...
